A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy - PubMed
4 hours ago
- #mRNA Therapeutics
- #Immunotherapy
- #Ovarian Cancer
- Developed CLDN6 nanobody-based bispecific T-cell engager (BiTE) using self-amplifying mRNA and lipid nanoparticles for targeted ovarian cancer therapy.
- CLDN6-Nb-BiTE demonstrated robust in vitro cytotoxicity and cytokine release, and in vivo tumor control without systemic toxicity.
- This approach overcomes limitations of protein-based BiTEs, offering a promising immunotherapy for ovarian cancer with potential for durable treatment.